Table 1.
Demographics of the patient populations included in the Hybrid Convergent ablation studies
| Study | Study population |
Male, n (%) | Duration of AF (y), mean ± SD or median (IQR) | LA size (cm), mean ± SD | Prior PVI, n (%) | Age (y), mean ± SD | EF (%) | Number of failed AADs, mean ± SD | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total, N | Paroxysmal AF, n (%) | Persistent AF, n (%) | LSPAF, n (%) | ||||||||
| DeLurgio et al 202010 | 102 | 0 (0) | 64 (63) | 38 (37) | 80 (78) | 4.4 ± 4.8 | 4.4 ± 0.6 | 0 (0) | 63.7 ± 9.6 | 55.3 ± 7.8 | 1.3 ± 0.57 |
| Makati et al 202022 | 226† | 3 (1.5) | 79 (38.1) | 125 (60.4) | 155 (70) | 5.08 ± 6.20 | NR | NR | 65.1 ± 9.5 | NR | NR |
| Maclean et al 202021 | 43 | 0 (0) | 0 (0) | 43 (100) | 32 (74) | 3 | 4.74 ± 0.63 | 15 (34.8) | 68.6 ± 7.7 | 50 | NR |
| Gulkarov et al 201918 | 31 | 0 (0) | 16 (52) | 15 (48) | 21 (68) | 2 (0.8–4.0) | 4.3 | NR | 62 | 50 | ≥1 |
| Larson et al 202020 | 113 | 14 (12) | 99 (88) | 85 (75) | 5.1 ± 4.6 | 4.8 ± 0.7 | 50 (44) | 63 ± 8.7 | 50.0 ± 11.0‡ 49.0 ± 13.2§ |
NR | |
| Tonks et al 201919 | 36 | 4 (11) | 32 (89) | 26 (72) | NR | <4.0: (n = 15; 41.7%) >4.0: (n = 21; 58.3%) |
6 (16.7) | 61 | ≥50: (n = 26; 73%) 31–49: (n = 6; 16.7%) <30 (n = 4; 11%) |
≥1: 100% 2: 27.8% 3: 2.8% |
|
AAD = antiarrhythmic drug; AF = atrial fibrillation; EF = ejection fraction; IQR = interquartile range; LA = left atrium; LSPAF = longstanding persistent atrial fibrillation; NR = not reported; PVI = pulmonary vein isolation; SD = standard deviation.
†
Of total 226 patients, 207 had known AF type.
‡
Group with continuous monitoring.
§
Group without continuous monitoring.